CompletedNCT04521478
A Study to Test the Effect of Different Doses of BI 1358894 and Quetiapine in People With Depression
Researchers compared BI 1358894, placebo and Quetiapine to find out how the approaches affected depression symptoms in people with depression.
Medication studyAges 18–65Multiple countries
Understand this study
What did researchers investigate?
Researchers compared BI 1358894, placebo and Quetiapine to find out how the approaches affected depression symptoms in people with depression.
Who was this study for?
Listed age limits: 18 years to 65 years.
- Listed locations
- Birmingham and 119 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateStarted: November 20, 2020
- Recruitment status
- Completed
- Enrollment listed in the registry
- 389
- Sponsor
- Boehringer Ingelheim
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States, Australia, France, ...
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT04521478
- Official title
Show the full official title
A Phase II, 6-week, Multicenter, Randomized, Double-blind, Double-dummy, Placebo-controlled, Parallel Group Trial With a Quetiapine Arm to Evaluate the Efficacy, Tolerability and Safety of Oral BI 1358894 in Patients With Major Depressive Disorder With Inadequate Response to Antidepressants.
Get this study by email
Recruitment & locations
CompletedBirmingham, United States · Garden Grove, United States · Long Beach, United States
98 more locations
- Sherman Oaks, United States
- Temecula, United States
- Torrance, United States
- Denver, United States
- Cromwell, United States
- Hartford, United States
- Fort Myers, United States
- Gainesville, United States
- Jacksonville, United States
- Miami, United States
- Atlanta, United States
- Chicago, United States
- Wichita, United States
- Flowood, United States
- O'Fallon, United States
- Cherry Hill, United States
- Marlton, United States
- New York, United States
- Cincinnati, United States
- Columbus, United States
- Allentown, United States
- Moosic, United States
- Everett, United States
- CABA, Argentina
- Córdoba, Argentina
- La Plata, Argentina
- Rosario, Argentina
- Southport, Australia
- Frankston, Australia
- Melbourne, Australia
- Burgas, Bulgaria
- Plovdiv, Bulgaria
- Sofia, Bulgaria
- Calgary, Canada
- Kelowna, Canada
- Mississauga, Canada
- Toronto, Canada
- Hradec Králové, Czechia
- Kladno, Czechia
- Ostrava, Czechia
- Pilsen, Czechia
- Prague, Czechia
- Dijon, France
- Douai, France
- Élancourt, France
- Montpellier, France
- Nantes, France
- Nice, France
- Nîmes, France
- Saint-Cyr-sur-Loire, France
- Toulouse, France
- Bad Homburg, Germany
- Frankfurt am Main, Germany
- Mainz, Germany
- Mannheim, Germany
- Stralsund, Germany
- Westerstede, Germany
- Budapest, Hungary
- Gyöngyös, Hungary
- Chiba, Ichikawa, Japan
- Fukuoka, Fukuoka, Japan
- Hokkaido, Sapporo, Japan
- Hyogo, Amagasaki, Japan
- Hyogo, Kobe, Japan
- Kanagawa, Kawasaki, Japan
- Kanagawa,Sagamihara, Japan
- Kumamoto, Kumamoto, Japan
- Nagasaki, Nagasaki, Japan
- Nara, Kashihara, Japan
- Saga, Karatsu, Japan
- Saga, Tosu, Japan
- Tokyo, Kodaira, Japan
- Tokyo, Minato-ku, Japan
- Tokyo, Setagaya-ku, Japan
- Tokyo, Shibuya-ku, Japan
- Tokyo, Shinjuku-ku, Japan
- Tokyo, Toshima-ku, Japan
- Gdansk, Poland
- Lodz, Poland
- Lublin, Poland
- Poznan, Poland
- Moscow, Russia
- Saint Petersburg, Russia
- Saratov, Russia
- Smolensk, Russia
- Banská Bystrica, Slovakia
- Bratislava, Slovakia
- Košice, Slovakia
- Svidník, Slovakia
- Trenčín, Slovakia
- Vranov nad Topľou, Slovakia
- Alcorcón, Spain
- Barcelona, Spain
- Jerez de la Frontera, Spain
- Madrid, Spain
- Salamanca, Spain
- Czechia
- Russia
Questions about this study
What did researchers investigate?
Researchers compared BI 1358894, placebo and Quetiapine to find out how the approaches affected depression symptoms in people with depression.
Who is behind this study?
The study sponsor is Boehringer Ingelheim.
Did this study involve medication?
Yes. The study involved medication, including BI 1358894, Placebo and Quetiapine.
Who was this study for?
Listed age limits: 18 years to 65 years.
